Shanghai Henlius (复宏汉霖) IPO: Newsflow on HLX10 Clinical Trial and ASEAN Commercialization
Shanghai Fosun Pharmaceutical (Group) (2196 HK), the parent company of Shanghai Henlius which in the process of book building today to raise up to...
551 Views
TOT Biopharm (东曜药业) IPO: Valuation of Core Product TAB008, a Bevacizumab Biosimilar
TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing in its Hong Kong...
556 Views
Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End
Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...
509 Views
Shanghai Henlius (复宏汉霖) IPO: Thoughts on Price Range, Cornerstone, Valuation Trap
Shanghai Henlius, a biotech subsidiary of Fosun Pharma, launched book building today to raise up to USD 477 million. In our previous insights...
620 Views
ECM Weekly (7 Sep 2019) - China Merchants Comm REIT, Immunotech Bio, Bank of Guizhou, XD, Huize
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
516 Views